116570 DTPA 0.3 (Boostrix)-012 EXT: 001: An open, phase III, non-randomized, multi-center study to assess the immunogenicity and safety of a booster dose of GlaxoSmithKline (GSK) Biologicals' combined reduced antigen content di
- Yogev, Ram (PD/PI)
Project: Research project